Arcadia Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(7,038) | $(13,986) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Change in fair value of common stock warrant and option liabilities | 1,474 | (6,544) |
| Issuance and offering costs allocated to liability classified options | — | 430 |
| Valuation loss on March 2023 PIPE | — | 6,076 |
| Depreciation | 113 | 287 |
| Lease amortization | 652 | 697 |
| Amortization of note receivable discount | (157) | — |
| Gain on disposal of property and equipment | (65) | (40) |
| Gain on sale of RS durum wheat trait | (4,000) | — |
| Stock-based compensation | 512 | 717 |
| Bad debt expense | — | 20 |
| Write-down of inventories | 154 | 444 |
| Impairment of property and equipment | 36 | — |
| Impairment of ROU asset | — | 113 |
| Write-down of non-controlling interest | 138 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other receivables | (762) | 184 |
| Inventories | 550 | (2,419) |
| Prepaid expenses and other current assets | (124) | 1 |
| Other noncurrent assets | 72 | 2 |
| Accounts payable and accrued expenses | (303) | (522) |
| Amounts due to related parties | (29) | 10 |
| Operating lease payments | (850) | (764) |
| Net cash used in operating activities | (9,627) | (15,294) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale of property and equipment | 334 | 115 |
| Proceeds from sale of Verdeca — earn-out received | — | 569 |
| Proceeds from sale of investments | 5,024 | 2,502 |
| Proceeds from sale of RS durum wheat trait | 4,000 | — |
| Cash paid related to sale of GoodWheat | (2,000) | — |
| Purchases of property and equipment | (16) | (5) |
| Purchases of investments | — | (7,525) |
| Net cash provided by (used in) investing activities | 7,342 | (4,344) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE | — | 5,997 |
| Payments of offering costs relating to March 2023 PIPE | — | (497) |
| Proceeds from ESPP purchases | 9 | 12 |
| Net cash provided by financing activities | 9 | 5,512 |
| Net decrease in cash and cash equivalents | (2,276) | (14,126) |
| Cash and cash equivalents — beginning of period | 6,518 | 20,644 |
| Cash and cash equivalents — end of period | $4,242 | $6,518 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||
| NONCASH TRANSACTIONS: | ||
| Common stock options issued to placement agent and included in offering costs related to March 2023 PIPE | $— | $212 |
| Warrant and option modifications included in Valuation loss on March 2023 PIPE | $— | $404 |
| Proceeds from sale of property and equipment in accounts receivable and other receivables | $— | $8 |
| Right of use assets obtained in exchange for new operating lease liabilities | $86 | $— |
| Note receivable recognized from sale of GoodWheat | $5,705 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.